Sixth monovalent XBB.1.5 vaccine elicits robust immune response against emerging SARS-CoV-2 variants in heart transplant recipients
Authors:
- 24 March 2024
- journal article
- research article
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 43 (7) , 1188-1192
Abstract
No abstract availableKeywords
This publication has 8 references indexed in Scilit:
- XBB.1.5 monovalent mRNA vaccine booster elicits robust neutralizing antibodies against XBB subvariants and JN.1Cell Host & Microbe, 2024
- Early Estimates of Updated 2023–2024 (Monovalent XBB.1.5) COVID-19 Vaccine Effectiveness Against Symptomatic SARS-CoV-2 Infection Attributable to Co-Circulating Omicron Variants Among Immunocompetent Adults — Increasing Community Access to Testing Program, United States, September 2023–January 2024MMWR. Morbidity and Mortality Weekly Report, 2024
- BNT162b2‐vaccine‐induced neutralization responses are immune correlates of clinical protection against SARS‐CoV‐2 in heart transplant recipientsClinical Transplantation, 2023
- Fifth bivalent omicron BA.4/BA.5 vaccination neutralization of SARS-CoV-2 in heart transplant recipientsThe Journal of Heart and Lung Transplantation, 2023
- Severity of SARS-CoV-2 Omicron variant infection in heart transplant recipientsThe Journal of Heart and Lung Transplantation, 2023
- Fourth BNT162b2 vaccination neutralization of omicron infection after heart transplantationThe Journal of Heart and Lung Transplantation, 2022
- Quantifying excess deaths among solid organ transplant recipients in the COVID-19 eraAmerican Journal of Transplantation, 2022
- SARS-CoV-2 Variants in Patients with ImmunosuppressionNew England Journal of Medicine, 2021